



The Texas Society of Clinical Oncology (TxSCO) invites fellows, residents, and medical students with an interest in oncology to submit an abstract for presentation at the TxSCO Annual Conference on Friday, September 22 and Saturday, September 23, 2023, at the Hyatt Regency Frisco - Dallas.

Four (4) leading abstracts—selected by the committee will be presenting to professionals across the state of Texas. All winning first authors will be invited to attend the conference (travel expenses will be covered) and receive a monetary award of up to \$1,500. Additionally, all first authors may be awarded with a chance to display their research poster at the annual conference.

Abstracts are to be submitted electronically at [txsco2023.exordo.com](https://txsco2023.exordo.com) before the Friday, July 21, 2023.

**\*Note: You will be prompted to create a free account to submit your abstract (if you have not previously submitted).**

Abstract categories may address the myriad of issues facing oncology and **can be previously evaluated or presented**. Suggested topics include, but are not limited to:

- Medical Oncology
- Surgical Oncology
- Cardio-Oncology
- Survivorship
- Developmental Therapeutics
- Hematology
- Radiation Oncology
- Palliative Care
- Clinical Trials/Interventions
- Pediatric Oncology or Hematology or Bone Marrow Transplantation as a Modality
- Neuro-Oncology
- Case Series
- Pilot Studies
- Retrospective Chart Review

## **SUBMISSION INSTRUCTIONS**

- There is a 300-word limit, excluding spaces, authors, and institutions.
- The title of your abstract should include significant words that reflect the content of the abstract but not refer to the study results or conclusions. Do not use proprietary names alone in the title or body of the abstract. If necessary, you may include a proprietary name in parentheses directly after the generic name on first use in the body of the abstract.
- Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract. Take particular care to identify complex chemotherapy regimens accurately.
- Include a disclosure(s), your name, institution (affiliation), address, telephone number, and email address with your abstract. As the first author (presenter), you will receive all future correspondence from TxSCO. Verify that all co-authors are aware of the contents of the abstract and support its data. Include the name and institution for each co-author associated with the abstract.

Abstracts will be judged solely on the data included in the submitted abstract. Statements such as “further data will be available” are discouraged.

You will receive an email from TxSCO confirming receipt of the abstract.

**Questions?** Email Amanda Impellizzeri at [aimpellizzeri@acc-cancer.org](mailto:aimpellizzeri@acc-cancer.org) or visit [txsco.com](http://txsco.com) for further details.